市場調査レポート
商品コード
1491669
ベアメタルステント市場:製品別、エンドユーザー別-2024-2030年の世界予測Bare-metal Stents Market by Product (Balloon Catheter, Balloon Expendable Stent, Metallic Stent), End Users (Ambulatory Surgical Centers, Cardiac Catheterization Laboratories, Hospitals) - Global Forecast 2024-2030 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
ベアメタルステント市場:製品別、エンドユーザー別-2024-2030年の世界予測 |
出版日: 2024年06月05日
発行: 360iResearch
ページ情報: 英文 184 Pages
納期: 即日から翌営業日
|
ベアメタルステント市場規模は、2023年に62億3,000万米ドルと推定され、2024年には65億7,000万米ドルに達し、CAGR 5.66%で2030年には91億7,000万米ドルに達すると予測されています。
ベアメタルステントは、閉塞した動脈を支え、開通させるための医療処置に使用されるメッシュ状の小さな金属チューブです。このタイプのステントは、冠動脈疾患により狭窄し閉塞した動脈を治療するための血管形成術と呼ばれる処置の際に使用されることが多いです。ステントは血流を回復させ、動脈が狭くなるのを防ぎます。薬剤溶出ステントとは異なり、ベアメタルステントには動脈内に薬剤を放出するコーティングはなく、単に金属材料でできています。ベアメタルステントの需要を牽引しているのは、冠動脈疾患などの心血管系疾患の世界の増加です。これらの疾患は依然として世界の主要死因の一つであるため、ステント留置術のような効果的で低侵襲なソリューションの必要性は極めて重要であり、成長し続けています。しかし、ベアメタルステントは製品回収による大きな課題に直面しています。このようなリコールは、患者に危害を及ぼす可能性のあるデバイスの不具合や安全性に関する問題に起因することが多いです。さらに、ベアメタルステントの製造技術の向上は、より精密で信頼性の高い製品を可能にしました。レーザー切断や生体適合性材料の改良などの技術により、これらのステントは耐腐食性にますます効果を発揮し、患者の転帰をより確実なものにしています。
主な市場の統計 | |
---|---|
基準年[2023] | 62億3,000万米ドル |
推定年[2024] | 65億7,000万米ドル |
予測年 [2030] | 91億7,000万米ドル |
CAGR(%) | 5.66% |
地域別インサイト
南北アメリカでは、成熟したヘルスケアシステムと心血管疾患の高い罹患率を反映して、米国とカナダがベアメタルステント市場で重要な役割を果たしています。南北アメリカの消費者は低侵襲手術に傾倒しており、ステント需要を牽引しています。最近の投資は、技術の進歩と再狭窄リスクの低減に重点が置かれています。市場への浸透度は高く、品質とブランドの評判が重視され、購買行動に影響を与えています。一方、EMEA市場は多様性に富んでおり、規制の厳格さが市場形成に重要な役割を果たしています。最近のEU医療機器規制は、安全性と有効性を重視するステント留置術の実施に影響を与えています。消費者の信頼は規制当局の承認に大きく依存しており、安定した需要はヘルスケアの規定と一致しています。さらに、アジア太平洋地域は人口が多く高齢化が進んでいるため、心血管疾患の有病率が高まり、その結果、ベアメタルステントを用いた治療に対する需要が高まっています。膨大な人口を抱える中国やインドなどの国々では、都市型ライフスタイルへの移行や、高血圧、糖尿病、肥満などの危険因子の増加により、冠動脈の症例数が増加しています。
FPNVポジショニング・マトリックス
FPNVポジショニングマトリックスは、ベアメタルステント市場におけるベンダーのポジショニングを評価する上で不可欠です。このマトリックスはベンダーの包括的な評価を提供し、事業戦略や製品満足度に関連する重要な指標を調査します。この詳細な評価により、ユーザーは自らの要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功のレベルを表す4つの象限、すなわちForefront(F)、Pathfinder(P)、Niche(N)、Vital(V)に分類されます。
市場シェア分析
市場シェア分析は、ベアメタルステント市場におけるベンダーの現状について、洞察に満ちた詳細な評価を提供する包括的なツールです。ベンダーの貢献度を綿密に比較・分析することで、各ベンダーの業績や市場シェア争いの際に直面する課題について、より深い理解を得ることができます。これらの貢献には、全体的な収益、顧客ベース、その他の重要な指標が含まれます。さらに、この分析では、調査した基準年の期間に観察された蓄積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合性に関する貴重な考察を提供しています。このような詳細な情報を得ることで、ベンダーは市場競争において優位に立つために、より多くの情報に基づいた意思決定を行い、効果的な戦略を考案することができます。
戦略分析と推奨
戦略分析は、世界マーケットで確固たる足場を築こうとする組織にとって不可欠です。企業は、ベアメタルステント市場における現在の地位を徹底的に評価することで、長期的な願望に沿った情報に基づいた意思決定を行うことができます。この重要な評価には、組織のリソース、能力、全体的なパフォーマンスを徹底的に分析し、中核となる強みと改善すべき領域を特定することが含まれます。
[184 Pages Report] The Bare-metal Stents Market size was estimated at USD 6.23 billion in 2023 and expected to reach USD 6.57 billion in 2024, at a CAGR 5.66% to reach USD 9.17 billion by 2030.
A bare-metal stent is a small, mesh-like metal tube used in medical procedures to support and keep open a blocked artery. This type of stent is often used during a procedure called angioplasty to treat arteries that have been narrowed and blocked due to coronary artery disease. The stent helps restore blood flow and prevents the artery from narrowing. Unlike drug-eluting stents, bare-metal stents do not have a coating that releases medication into the artery; they are simply made of metal materials. The rising prevalence of cardiovascular conditions, such as coronary artery diseases, across the globe acts as a primary driver for the demand for bare-metal stents. As these diseases remain among the leading causes of death worldwide, the need for effective, minimally invasive solutions such as stenting is crucial and continues to grow. However, bare-metal stents have faced significant challenges due to product recalls. Such recalls often stem from issues related to device malfunctions or safety concerns that could potentially harm patients. Moreover, the improvements in manufacturing technologies for bare-metal stents have allowed for more precise and reliable products. With techniques such as laser cutting and improved biocompatible materials, these stents are increasingly effective in resisting corrosion and ensuring better patient outcomes.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 6.23 billion |
Estimated Year [2024] | USD 6.57 billion |
Forecast Year [2030] | USD 9.17 billion |
CAGR (%) | 5.66% |
Regional Insights
In the Americas, the United States and Canada are significant players in the bare-metal stents market, reflecting a mature healthcare system and high incidence rates of cardiovascular diseases. Consumers in the Americas are inclined towards minimally invasive procedures, driving demand for stents. Recent investments have focused on technological advancements and reducing the risk of restenosis. Market penetration is high, and the focus is on quality and brand reputation, influencing purchasing behaviors. On the other hand, the EMEA market is diverse, with regulatory rigor playing a critical role in shaping the market. Recent EU Medical Device Regulations have impacted stenting practices, with a strong emphasis on safety and efficacy. Consumer trust is highly dependent on regulatory approvals, and a steady demand is aligned with healthcare provisions. Moreover, the Asia Pacific region has a large and aging population, which increases the prevalence of cardiovascular diseases and, thus, the demand for interventions involving bare-metal stents. Countries such as China and India, with their vast populations, are seeing higher numbers of coronary artery cases due to shifts towards urban lifestyles and increased occurrences of risk factors such as hypertension, diabetes, and obesity.
Market Insights
The market dynamics represent an ever-changing landscape of the Bare-metal Stents Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Bare-metal Stents Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Bare-metal Stents Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
FDA Approves Boston Scientific's AGENT Drug-Coated Balloon, Enhancing Peripheral Artery Disease Treatments
Boston Scientific has received FDA approval for its AGENT Drug-Coated Balloon, a pivotal development in treating peripheral artery disease (PAD). This new medical device is designed to maintain arterial openness and prevent re-blockage, addressing a common issue in PAD therapies. The approval is based on positive outcomes from clinical trials that demonstrated significant improvements in patient conditions with minimal risks. This development marks a significant milestone in vascular medicine, promising enhanced treatment solutions for patients suffering from arterial diseases. [Published On: 2024-03-01]
Kaneka Corporation Enhances Stent Development Capabilities with Acquisition of JMDT
Kaneka Corporation enhanced its position in the medical device sector by acquiring all shares of Japan Medical Device Technology Co., Ltd. (JMDT), a prominent developer and manufacturer of medical devices located in Kamimashiki-gun, Kumamoto. This strategic acquisition positions Kaneka as a fully integrated company in the endovascular catheter market, particularly focusing on coronary artery disease treatments through stenting, a segment worth 30 billion yen in Japan. [Published On: 2023-11-30]
FDA Greenlights Medinol's Innovative Drug-Eluting Coronary Stent
The U.S. Food and Drug Administration (FDA) has officially approved the use of Medinol's latest drug-eluting stent in coronary artery interventions. This state-of-the-art stent integrates medication that actively prevents artery re-blockage, a common issue post-surgery. Key features of the stent include its enhanced design, which significantly betters its flexibility and positioning accuracy compared to traditional bare-metal stents. This approval marks a significant milestone in coronary treatment options, offering enhanced effectiveness and safety, thereby improving patient outcomes in managing coronary artery disease. [Published On: 2023-10-24]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Bare-metal Stents Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Bare-metal Stents Market, highlighting leading vendors and their innovative profiles. These include Abott Laboratories, ACE CARDIOPATHY, B. Braun SE, Becton, Dickinson and Company, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, Cook Group Incorporated, Medtronic PLC, MeKo Manufacturing e.K., Meril Life Sciences Pvt Ltd., MicroPort Scientific Corporation, Relisys Medical Devices Limited, SLTL Group, STENTYS SA, Stryker Corporation, Terumo Corporation, and Translumina Therapeutics.
Market Segmentation & Coverage